VPTDF - Ventripoint Applauds the US Government for Establishing an Additional Payment to Doctors for Analyzing 3D Heart Scans
(TheNewswire)
Toronto, Ontario – TheNewswire –November 29, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased that the U.S. Department of Health andHuman Services (HHS) through CMS (Centers for Medicare & MedicaidServices) has approved a new compensation for doctors to analyze 3Dechocardiograms.
“3D echocardiograms are regarded as the futuretechnique for heart analysis due to the speed of collecting a singleholographic image of the whole heart and the extra fee forcardiologists for analyzing these scans should accelerate the adoptionof 3D technology,” stated Dr. George Adams CEO of Ventripoint.“The unique ability of the VMS+ technology to analyze both 2D and 3Dimage datasets for the whole heart makes for a bright future for theCompany.”
At the recommendation of the AMA (American MedicalAssociation), the CMS has finalized a CPT (Current ProceduralTerminology) billing code (+93319) for 3D echocardiographic imagingand postprocessing during transesophageal or transthoracicechocardiography. Effective January 1, 2022, the CPT billing codecan be used by doctors and hospitals to claim reimbursement frompayers (Medicare, Medicaid, insurance companies, etc.).
This is a significant development for 3Dechocardiography, which has struggled to be adopted due to poor imagequality and difficulty of analysis. Our 3D echo VMS+ product hasrecently been shown ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8250005/ ) to yield excellent results in 75% of children for the mostdifficult heart chamber, the right ventricle. The Company believes itcan accelerate the adoption of 3D echocardiography by improving theease and success rate of reading the exams and generating MRI-grademeasurements for all 4 chambers of the heart.
There will always be a need for VMS+3.0 to analyze 2Dechocardiography exams for the 25% of patients who generate unreadableimages in 3D scans. The VMS+ systems (2D and 3D) are fast andreliable ways to assist in diagnosing and monitoring patients withheart defects and other cardiac issues. Now the VMS+ 3D can alsohelp in driving the adoption of an additional source of billableincome for doctors.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.